

ASX ANNOUNCEMENT

5 December 2024

Denmark positioned as EU medicinal cannabis hub

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce the Danish government’s agreement to make the country’s medicinal cannabis pilot program permanent as well as implement an improved framework for cultivation and export.



The agreement underscores Denmark’s recognition of the economic advantages and growth potential of this emerging sector and helps bolster LGP’s position as a leader in the European medicinal cannabis market.

Strategic advancements in cultivation and export rules

Denmark’s revised framework introduces several proposed changes to cultivation and export rules that would unlock substantial value for Danish producers, including Little Green Pharma:

- Historically, Danish producers were at a competitive disadvantage as they were unable to use any form of pesticide, limiting yield optimisation and increasing costs. The proposed changes would bring Denmark in line with international standards and improve cost-efficiencies.
- Previously, Danish producers were restricted from importing cannabis products. This change means producers like LGP can now use their facilities as their European hub to improve logistics, reduce costs, and reduce the risk of product expiry.
- The importation restrictions also meant Danish producers had to rely exclusively on local service providers for some services, while being unable to offer their own services to foreign entities. The new framework would introduce price competition for local service providers and give LGP the ability to offer services such as GMP testing and packing.
- The changes also give LGP the potential to expand its production footprint beyond flower by allowing the importation of API material.

Key access changes proposed for patients and prescribers

- Danish patients will have consistent access to medicinal cannabis prescribed by healthcare professionals, supporting safer and more regulated treatment pathways.
- The government will continue to subsidise up to 50% of medicinal cannabis costs, capped at DKK 10,000 annually per patient.
- Updated guidelines will improve prescribing practices, providing doctors with better resources and a simplified summary for patient education
- A planned review of medical driving bans for medicinal cannabis patients will help harmonise Denmark with more lenient international standards

A broader European context: Strategic alignment with France and Germany

Denmark's policy evolution demonstrates a clear strategic alignment with medicinal cannabis market developments in Germany and France:

- with recreational cannabis legalisation and the easing of restrictions on medicinal use, Germany has emerged as the largest federally legal cannabis market globally. Denmark's enhanced framework follows this progressive trajectory and aims to capture similar economic and healthcare benefits.
- Denmark's decision to make its scheme permanent highlights a commitment to long-term economic and healthcare growth that resonates with similar initiatives in France.

The agreement has been reached by all political parties in the Danish government and if legislated, will position Denmark as an important player in the European medicinal cannabis market, leveraging its advanced regulatory framework and production capabilities to strengthen cross-border trade.

Paul Long, CEO of Little Green Pharma, said:


"Denmark's proposed permanent medicinal cannabis framework not only underscores its leadership in the European market but also highlights the immense economic and therapeutic potential of this emerging industry. The alignment with broader European trends in Germany and France reinforces the strategic importance of LGP's investment in Denmark. These advancements will empower us to expand our footprint, improve patient access, and contribute to the growth of a robust, globally competitive medicinal cannabis sector."



For further information see:

<https://bit.ly/3VixfkM>

<https://bit.ly/3ZhoSH7>



Alistair Warren
Company Secretary

ENDS
BY ORDER OF THE BOARD



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: cosec@lgp.global
T: +61 8 6280 0050

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma and Reset Mind Sciences

Little Green Pharma Group is a global, vertically integrated and geographically diverse medicinal cannabis and psychedelics business with operations from cultivation and production through to manufacturing, distribution and clinical services.

The Company has three global production sites for the manufacture of its own-branded and white-label ranges of medicinal cannabis and psychedelic products, being a Danish glasshouse facility and West Australian indoor craft production facility with a combined nameplate capacity of 30 tonnes of cannabis biomass per annum, and a combined psychedelics clinic, head office and therapeutic goods manufacturing facility located in Western Australia.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets and delivers psychedelic assisted psychotherapy services via its wholly-owned Reset Mind Sciences business.

The Company has a strong focus on patient access in global medicinal cannabis markets and the Australian psychedelic market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com and Reset Mind Sciences: <https://www.resetmind.com.au/>

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.investorcentre.com/au

LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>